---
title: "Top Verastem Executives Quietly Cash Out in Fresh Stock Moves"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290771767.md"
description: "Verastem executives Dan Paterson and Daniel Calkins sold shares totaling over $104,000 on June 24, 2026. This insider selling coincides with preliminary positive data for KRAS inhibitor VS-7375 and plans for Phase 3 trials. However, Jefferies lowered its price target citing a crowded market, while TipRanks' AI analyst rates VSTM as Neutral due to weak financials and cash burn despite pipeline progress."
datetime: "2026-06-25T02:04:46.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290771767.md)
  - [en](https://longbridge.com/en/news/290771767.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290771767.md)
---

# Top Verastem Executives Quietly Cash Out in Fresh Stock Moves

New insider activity at Verastem ( (VSTM) ) has taken place on June 24, 2026.

Verastem has seen notable insider selling, as President & CEO Dan Paterson offloaded 20,871 shares of the company’s stock in a transaction valued at $87,240. Adding to the activity, CFO Daniel Calkins sold 4,089 shares, generating proceeds of $17,089. These transactions highlight recent executive-level moves within Verastem’s leadership team.

Verastem shares traded around biotech news as the company released preliminary TARGET-D 101 results for KRAS G12D inhibitor VS-7375, showing early anti-tumor activity and a favorable safety profile across pancreatic, colorectal and lung cancers, and outlined an aggressive path to Phase 3 trials. At the same time, Jefferies cut its price target because the KRAS space is becoming crowded and differentiation is seen as harder, while other assessments cited Verastem’s heavy losses, cash burn and weak technicals, partially offset by positive trial updates and a stronger pipeline outlook.

**Spark’s Take on VSTM Stock**

According to Spark, TipRanks’ AI Analyst, VSTM is a Neutral.

The score is held down primarily by weak financial fundamentals—very large operating losses and substantial ongoing cash burn—despite strong recent revenue growth and decent gross margins. Technicals remain bearish to neutral with the stock below key moving averages and negative MACD. Positives from the earnings call and recent pipeline/catalyst news support the outlook, but do not fully offset near-term funding and execution risk; valuation is difficult to anchor given the negative P/E and no dividend yield provided.

To see Spark’s full report on VSTM stock,  
click here.

**More about Verastem**

**YTD Price Performance:** -45.47%

**Average Trading Volume:** 2,294,276

**Technical Sentiment Signal:** Sell

**Current Market Cap:** $373.5M

### Related Stocks

- [VSTM.US](https://longbridge.com/en/quote/VSTM.US.md)
- [JEF.US](https://longbridge.com/en/quote/JEF.US.md)

## Related News & Research

- [Verastem Stock Jumps As Data Shows Strong Survival Trends In Pancreatic Cancer](https://longbridge.com/en/news/290083508.md)
- [Verastem Advances VS-7375 Into Phase 2 Pancreatic Trial](https://longbridge.com/en/news/290061220.md)
- [Cullinan Therapeutics (CGEM) Expected to Release Quarterly Earnings on Thursday](https://longbridge.com/en/news/294341758.md)
- [Cullinan to launch registrational Phase 2 CLN-049 trial in relapsed/refractory AML in Q3 2026](https://longbridge.com/en/news/294054305.md)
- [PCSA: Acquisition brings a novel BTK inhibitor and $200M funding to advance three parallel clinical programs](https://longbridge.com/en/news/294217251.md)